Table 2 Univariate and multivariate analysis of traditional and biomarkers for rapid GFR decline

SBP (mmHg)

1.03 (1.02, 1.05)

< 0.001

1.03 (1.01, 1.06)

0.002

1.03 (1.01, 1.05)

0.015

1.02 (1, 1.04)

0.102

DBP (mmHg)

1.04 (1.01, 1.06)

0.006

1.02 (0.98, 1.05)

0.357

1.03 (0.99, 1.07)

0.119

1.04 (1, 1.08)

0.052

GFR (mL/min/1.73m²)

0.98 (0.97, 0.99)

0.003

0.99 (0.98, 1.01)

0.506

1 (0.98, 1.02)

0.852

1.01 (0.99, 1.03)

0.59

Age

0.99 (0.96, 1.02)

0.547

0.99 (0.96, 1.03)

0.776

1.02 (0.98, 1.06)

0.379

1.02 (0.99, 1.06)

0.211

Male

1.02 (0.52, 2.01)

0.947

1.54 (0.72, 3.31)

0.263

1.18 (0.54, 2.57)

0.677

1.07 (0.49, 2.35)

0.858

Use of RAAS blockers

0.59 (0.31, 1.14

0.115

0.64 (0.27, 1.5)

0.301

0.92 (0.4, 2.09)

0.834

0.8 (0.34, 1.9)

0.616

UACR (mg/gCr)

1.01 (1.01, 1.02)

< 0.001

1.01 (1.01, 1.02)

< 0.001

1.01 (1.01, 1.02)

< 0.001

1.01 (1.01, 1.02)

0.003

UMCP-1 (ng/mgCr)

1.03 (1.01, 1.05)

0.004

0.93 (0.89, 0.97)

0.001

UEGF (ng/mgCr)

0.98 (0.97, 0.99)

0.011

0.99 (0.97, 1.01)

0.274

UEGF/MCP-1 (ng/ng)

0.97 (0.95, 0.99)

0.001

0.97 (0.94, 0.99)

0.018